Results 151 to 160 of about 4,821 (183)
Some of the next articles are maybe not open access.
American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2021
The peptide hormone amylin reduces food intake and body weight and is an attractive candidate target for novel pharmacotherapies to treat obesity. However, the short half-life of native amylin and amylin analogs like pramlintide limits these compounds’ potential utility in promoting sustained negative energy balance.
Lauren M. Stein +9 more
openaire +2 more sources
The peptide hormone amylin reduces food intake and body weight and is an attractive candidate target for novel pharmacotherapies to treat obesity. However, the short half-life of native amylin and amylin analogs like pramlintide limits these compounds’ potential utility in promoting sustained negative energy balance.
Lauren M. Stein +9 more
openaire +2 more sources
Expert Opinion on Investigational Drugs, 2001
Amylin is a peptide hormone which is co-secreted with insulin from the pancreatic beta-cell. Type 1 diabetic individuals and some Type 2 diabetic individuals are characterised by amylin deficiency. Animal experiments have revealed several actions of amylin on intermediary metabolism, of these some have been demonstrated to be of potential physiological
Schmitz, O. +3 more
openaire +3 more sources
Amylin is a peptide hormone which is co-secreted with insulin from the pancreatic beta-cell. Type 1 diabetic individuals and some Type 2 diabetic individuals are characterised by amylin deficiency. Animal experiments have revealed several actions of amylin on intermediary metabolism, of these some have been demonstrated to be of potential physiological
Schmitz, O. +3 more
openaire +3 more sources
European Journal of Pharmacology, 2023
Long-acting dual amylin and calcitonin receptor agonists (DACRAs) hold great promise as potential treatments for obesity and its associated comorbidities. These agents have demonstrated beneficial effects on body weight, glucose control, and insulin action mirroring the effects observed with glucagon-like peptide-1 (GLP-1) agonist treatment. Strategies
Anna Thorsø Larsen +2 more
openaire +2 more sources
Long-acting dual amylin and calcitonin receptor agonists (DACRAs) hold great promise as potential treatments for obesity and its associated comorbidities. These agents have demonstrated beneficial effects on body weight, glucose control, and insulin action mirroring the effects observed with glucagon-like peptide-1 (GLP-1) agonist treatment. Strategies
Anna Thorsø Larsen +2 more
openaire +2 more sources
Diabetes, 2023
Long-acting dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for the treatment of type 2 diabetes and obesity due to their beneficial effects on both body weight, glucose control and insulin action. However, whether DACRAs affect hypertension, and diabetes-related cardiovascular complications remain unknown. In this study, the
SIMONE A. MELANDER +4 more
openaire +1 more source
Long-acting dual amylin and calcitonin receptor agonists (DACRAs) are novel candidates for the treatment of type 2 diabetes and obesity due to their beneficial effects on both body weight, glucose control and insulin action. However, whether DACRAs affect hypertension, and diabetes-related cardiovascular complications remain unknown. In this study, the
SIMONE A. MELANDER +4 more
openaire +1 more source
Diabetes, 2023
Dual amylin and calcitonin receptor agonists (DACRAs) are potential therapeutic candidates for treatment of obesity. Preclinical studies have shown favorable effects of DACRAs on appetite regulation contributing to a reduction in body weight. Interestingly, the DACRA-induced effects on weight loss are superior to the effects of a suppressed food intake,
EMILIE A. PETERSEN +6 more
openaire +1 more source
Dual amylin and calcitonin receptor agonists (DACRAs) are potential therapeutic candidates for treatment of obesity. Preclinical studies have shown favorable effects of DACRAs on appetite regulation contributing to a reduction in body weight. Interestingly, the DACRA-induced effects on weight loss are superior to the effects of a suppressed food intake,
EMILIE A. PETERSEN +6 more
openaire +1 more source
Structure, Self-Association, and Aggregation Properties of a Long-Acting Amylin Receptor Agonist
Molecular PharmaceuticsPharmacokinetic (PK) properties of therapeutic peptides can be extended through covalent conjugation to albumin-binding fatty acids. The present study examines the effects of fatty acid conjugation and vehicle composition on structure, self-association pattern, and aggregation propensity of an amylin analogue.
Christian Poulsen +3 more
openaire +2 more sources
American Journal of Physiology-Endocrinology and Metabolism, 2014
The present study investigated a novel oral dual amylin and calcitonin receptor agonist (DACRA), KBP-042, in head-to-head comparison with salmon calcitonin (sCT) with regard to in vitro receptor pharmacology, ex vivo pancreatic islet studies, and in vivo proof of concept studies in diet-induced obese (DIO) and Zucker diabetic fatty (ZDF) rats. In vitro,
Andreassen, Kim V +8 more
openaire +3 more sources
The present study investigated a novel oral dual amylin and calcitonin receptor agonist (DACRA), KBP-042, in head-to-head comparison with salmon calcitonin (sCT) with regard to in vitro receptor pharmacology, ex vivo pancreatic islet studies, and in vivo proof of concept studies in diet-induced obese (DIO) and Zucker diabetic fatty (ZDF) rats. In vitro,
Andreassen, Kim V +8 more
openaire +3 more sources
894-P: MET-233 Is an Ultra-Long-Acting Amylin Receptor Agonist
DiabetesIntroduction and Objective: MET-233 is an ultra-long acting (ULA) amylin analog being evaluated in clinical trials for the treatment of obesity. We sought preclinical proof of concept that MET-233, designed to be combined with GLP-1R agonist MET-097, is an effective candidate for obesity treatment. Methods: MET-233 emerged from an amylin
JAMES S. MINNION +2 more
openaire +1 more source
789-P: Discovery of a Novel, Long-Acting Amylin Receptor Agonist for Body Weight Control
DiabetesIntroduction & Objective: Amylin, a hormone co-secreted with insulin from pancreatic beta-cells, reduces food intake and glucagon levels. Combination of GLP-1 and amylin analogs promotes weight loss and glucose control. However, treatment is complicated by the need to formulate the peptides in different buffers.
YAN LI +12 more
openaire +1 more source
Diabetes
Introduction and Objective: Eloralintide (Elora; LY3841136) is a potent, long acting once weekly (QW) amylin receptor agonist under development for obesity. Unlike other amylin agonist molecules (e.g. Cagrilintide), it is designed to have minimal calcitonin activity in the clinic.
SHOBHA N. BHATTACHAR +7 more
openaire +1 more source
Introduction and Objective: Eloralintide (Elora; LY3841136) is a potent, long acting once weekly (QW) amylin receptor agonist under development for obesity. Unlike other amylin agonist molecules (e.g. Cagrilintide), it is designed to have minimal calcitonin activity in the clinic.
SHOBHA N. BHATTACHAR +7 more
openaire +1 more source